Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure With Preserved Ejection Fraction: The CAMEO-DAPA TrialBarry A. Borlaug, Rickey E. Carter, Yogesh N.V. Reddy et al.|Circulation|2023Cited by 116
Interleukin-6 in Patients With Heart Failure and Preserved Ejection FractionAlessio Alogna, Barry A. Borlaug, Jair Machado Espindola Netto et al.|JACC Heart Failure|2023Cited by 111
Ventricular Stiffening and Chamber Contracture in Heart Failure with Higher Ejection FractionDejana Popović, Barry A. Borlaug, Alessio Alogna et al.|European Journal of Heart Failure|2023Cited by 65
Dapagliflozin and Right Ventricular–Pulmonary Vascular Interaction in Heart Failure With Preserved Ejection FractionYogesh N.V. Reddy, Barry A. Borlaug, Rickey E. Carter et al.|JAMA Cardiology|2024Cited by 40
Hypoxaemia in Patients with Heart Failure and Preserved Ejection FractionMassar Omar, Barry A. Borlaug, Kazunori Omote et al.|European Journal of Heart Failure|2023Cited by 24